ACCSCIENCE PUBLISHING

Brain & Heart

REVIEW ARTICLE

Autonomic dysfunction and cardiovascular outcomes: Pathophysiological mechanisms and clinical implications

Abdülmelik Birgün[1], Macit Kalçık[2]*, Muhammet Cihat Çelik[1], Mucahit Yetim[2], Lütfü Bekar[2], and Yusuf Karavelioğlu[2]

[1]Department of Cardiology, Hitit University Erol Olçok Education and Research Hospital, Corum, Turkey

[2]Department of Cardiology, Faculty of Medicine, Hitit University, Corum, Turkey

Abstract

The autonomic nervous system is fundamental for maintaining cardiovascular homeostasis by integrating sympathetic and parasympathetic activity across central and peripheral circuits. Disruption of this finely tuned regulation, known as autonomic dysfunction, has emerged as a critical determinant of cardiovascular risk. Mechanistically, autonomic imbalance is characterized by reduced vagal activity, impaired baroreflex sensitivity, and heightened sympathetic drive, all of which contribute to hemodynamic instability, arrhythmogenesis, and adverse clinical outcomes. Baroreflex sensitivity and heart rate variability have been identified as independent predictors of mortality in post-myocardial infarction patients and individuals with chronic heart failure, providing incremental prognostic value beyond left ventricular function and conventional risk factors. Moreover, systemic diseases such as diabetes mellitus can precipitate cardiovascular autonomic neuropathy, a complication associated with silent myocardial ischemia, arrhythmias, and increased mortality. Wearable sensors and artificial intelligence-based analytic platforms enable continuous and non-invasive monitoring of autonomic function, facilitating earlier detection of subclinical abnormalities and supporting the integration of autonomic indices into prognostic models. Beyond conventional heart rate variability, advanced autonomic markers such as deceleration capacity and heart rate turbulence, supported by guideline-endorsed testing strategies and digital monitoring tools, provide incremental prognostic value. These advances represent a major step toward personalized cardiovascular medicine, in which autonomic dysfunction can serve not only as a mechanistic explanation of disease but also as a therapeutic and preventive target. Recognition of its mechanistic, diagnostic, and prognostic implications is essential for developing innovative strategies to reduce cardiovascular morbidity and mortality.

Keywords: Autonomic nervous system dysfunction; Cardiovascular diseases; Heart rate variability; Baroreflex sensitivity; Sympathetic nervous system

***Corresponding author:**
Macit Kalçık
(macitkalcik@hitit.edu.tr)

Citation: Birgün A, Kalçık M, Çelik MC, Yetim M, Bekar L, Karavelioğlu Y. Autonomic dysfunction and cardiovascular outcomes: Pathophysiological mechanisms and clinical implications. *Brain & Heart*. 2026;4(2):025410059. doi: 10.36922/BH025410059

Received: October 7, 2025

Revised: December 20, 2025

Accepted: December 24, 2025

Published online: January 6, 2026

1. Introduction

The autonomic nervous system (ANS) orchestrates the fine balance between sympathetic and parasympathetic activity, ensuring cardiovascular stability under both resting and

stress conditions. Through its dynamic regulation of heart rate, vascular tone, and blood pressure, the ANS maintains adequate tissue perfusion and oxygen delivery across a wide spectrum of physiological demands.[1] Disruption of this balance, termed autonomic dysfunction, has emerged as a critical determinant of adverse cardiovascular outcomes.

According to the most recent estimates from the Global Burden of Disease study, cardiovascular diseases remain the leading cause of death worldwide, accounting for approximately 20.5 million deaths per year and contributing to more than 390 million disability-adjusted life years. Hypertension, ischemic heart disease, heart failure, and arrhythmias—conditions closely linked with autonomic dysfunction—represent the largest contributors to this global cardiovascular burden.[2]

Cardiovascular autonomic regulation depends on intricate neural circuits, baroreceptor reflexes, and efferent pathways that provide rapid adaptive responses. For instance, standing upright induces a reflex sympathetic activation to counteract venous pooling, while parasympathetic withdrawal facilitates tachycardia. Failure of this reflexive integration results in hemodynamic instability, such as orthostatic hypotension, as well as arrhythmogenic vulnerability.[3]

The clinical significance of autonomic dysfunction has been increasingly recognized over the past decades. Reduced vagal tone, heightened sympathetic drive, and impaired baroreflex sensitivity have been associated with hypertension, heart failure, atrial fibrillation, and sudden cardiac death.[4,5] Beyond these classical manifestations, autonomic impairment also intersects with systemic disorders, including diabetes mellitus and neurodegenerative diseases, further amplifying cardiovascular risk.[6]

Recent technological advances, such as wearable sensors and artificial intelligence-based signal analysis, have enabled a deeper exploration of autonomic markers in both clinical and population settings. These developments not only enhance diagnostic accuracy but also expand the potential for incorporating autonomic indices into prognostic models.[7]

Given its multifaceted role in cardiovascular health and disease, autonomic dysfunction represents both a mechanistic driver and a therapeutic target. This review aims to provide a comprehensive overview of pathophysiological mechanisms, clinical manifestations, diagnostic approaches, and therapeutic strategies, while also highlighting future directions in the integration of neural and cardiovascular data.

2. Pathophysiological mechanisms

Autonomic dysfunction arises from a complex interplay of neural, vascular, and inflammatory processes that converge to destabilize cardiovascular regulation. Several key mechanisms have been identified as central to this pathophysiological cascade.

2.1. Baroreflex impairment and arterial stiffness

The arterial baroreflex provides rapid adjustments in sympathetic and parasympathetic tone to stabilize blood pressure fluctuations. Impairment of this reflex—whether due to aging, vascular stiffening, or neural injury—leads to exaggerated blood pressure variability and impaired heart rate control. Reduced baroreflex sensitivity has been strongly associated with increased risk of adverse cardiovascular outcomes, particularly post-myocardial infarction (post-MI) mortality.[4,8] Furthermore, arterial stiffness diminishes baroreceptor responsiveness, creating a vicious cycle in which autonomic imbalance and vascular dysfunction reinforce each other[9] (Table 1 and Figure 1).

2.2. Heart rate variability

Heart rate variability (HRV), a non-invasive marker of autonomic tone, reflects the dynamic interplay between sympathetic and vagal influences on the sinoatrial node. Decreased HRV is consistently associated with heightened cardiovascular risk, including arrhythmias and sudden cardiac death.[10] While HRV reduction may reflect diminished vagal input, it also serves as a surrogate of global autonomic dysregulation. Importantly, HRV abnormalities often precede overt clinical manifestations, rendering it a valuable early marker of autonomic dysfunction[11] (Table 2).

2.3. Inflammation, oxidative stress, and endothelial dysfunction

Chronic low-grade inflammation and oxidative stress profoundly alter autonomic signaling. Elevated inflammatory cytokines such as interleukin-6 and tumor necrosis factor-alpha have been linked with reduced baroreflex sensitivity and lower HRV.[12] Oxidative stress impairs nitric oxide bioavailability, thereby disrupting endothelial function and further amplifying sympathetic overactivity.[13] These

Table 1. Baroreflex sensitivity in disease states

Disease condition	Typical baroreceptor findings	Prognostic implication
Hypertension	Reduced	Predicts target organ damage
Heart failure	Severely blunted	Associated with mortality
Diabetes	Impaired	Correlates with silent ischemia
Aging	Gradual decline	Explains orthostatic intolerance



Figure 1. The bidirectional relationship between arterial stiffness and baroreflex dysfunction. Increased arterial stiffness reduces baroreceptor strain, leading to impaired baroreflex sensitivity and heightened sympathetic activation. The resulting autonomic imbalance contributes to downstream hemodynamic consequences, perpetuating the cycle of cardiovascular dysregulation.

interactions provide a mechanistic bridge between systemic inflammation, vascular dysfunction, and adverse cardiovascular outcomes (Figure 2).

2.4. Neural control of the sinoatrial node and vascular tone

The sinoatrial node is tightly regulated by neural inputs, with parasympathetic activity exerting rapid beat-to-beat control and sympathetic activity modulating longer-term chronotropic responses. Autonomic imbalance at this level predisposes the myocardium to arrhythmias, particularly atrial fibrillation.[5,14] Beyond the heart, sympathetic overactivation drives vasoconstriction, increases afterload, and contributes to the progression of hypertension and heart failure.[15] These effects underscore the centrality of autonomic tone as a determinant of both electrophysiological stability and hemodynamic homeostasis.



Figure 2. This diagram summarizes the mechanistic cascade through which inflammatory cytokines (IL-6, TNF-α) promote oxidative stress and reduce nitric oxide bioavailability, thereby impairing endothelial function. These alterations enhance sympathetic activation, diminish parasympathetic tone, and ultimately result in autonomic imbalance. The pathway highlights the interconnected molecular processes underlying autonomic–vascular dysfunction.
Abbreviations: IL-6: Interleukin-6; ROS: Reactive oxygen species; TNF-α: Tumor necrosis factor alpha.

In summary, autonomic dysfunction emerges from an interwoven matrix of impaired baroreflexes, reduced HRV, inflammatory and oxidative processes, and abnormal neural control of cardiac and vascular function. These mechanisms not only explain the clinical spectrum of

Table 2. Comprehensive autonomic and heart rate variability parameters

Parameter	Measurement method	Physiological meaning	Clinical relevance
SDNN	Time-domain	Global autonomic function	Lower values predict post-MI mortality
RMSSD	Time-domain	Vagal modulation	Useful for short-term recordings; reduced in sympathetic dominance
pNN50	Time-domain	Parasympathetic activity	Reduced in diabetic autonomic neuropathy
LF power	Frequency-domain	Mixed sympathetic+parasympathetic	Elevated in stress, hypertension
HF power	Frequency-domain	Parasympathetic (vagal) activity	Suppressed in heart failure and AF
LF/HF ratio	Frequency-domain	Sympathovagal balance	Increased in sympathetic overactivity
Very low frequency (VLF)	Frequency-domain	Long-term autonomic/endothelial modulation	Low VLF predicts mortality post-MI
Ultra-low frequency (ULF)	Frequency-domain	Circadian/autonomic regulation	Reduced in advanced heart failure
Heart rate acceleration (AC)	Beat-to-beat interval analysis	Sympathetic reactivity	Elevated in adrenergic activation
Deceleration capacity (DC)	Phase-rectified signal averaging (PRSA)	Vagal braking/cardiac deceleration	Strong predictor of mortality after MI
Turbulence onset (TO)	Response to ventricular premature beats	Initial sinus acceleration (baroreflex)	Positive TO indicates impaired baroreflex
Turbulence slope (TS)	Regression slope after VPB	Sinus deceleration recovery	Low TS strongly predicts post-MI mortality
T-Wave alternans (TWA)	Microvolt-level ECG alternans	Ventricular electrical instability	Predicts sudden cardiac death risk

Formulas: RMSSD = $\sqrt{}$(mean of (RR (i+1) − RR (i))^2). pNN50 = % of consecutive NN intervals differing by>50 ms. Acceleration Capacity (AC) = PRSA-derived measure of sympathetic-mediated heart rate acceleration. Deceleration Capacity (DC) = PRSA-derived measure of vagal-mediated RR interval deceleration. Turbulence Onset (TO) = TO=100 × (RR_1+RR_2−$RR\text{-}_2$ − $RR\text{-}_1$)/($RR\text{-}_2$ + $RR\text{-}_1$); where $RR\text{-}_2$ and $RR\text{-}_1$ = pre-VPB RR intervals; RR_1 and RR_2=post-VPB RR intervals. Turbulence Slope (TS) = Maximum positive regression slope over any sequence of 5 consecutive RR intervals after VPB. T-Wave Alternans (TWA) = Alternating T-wave amplitude measured in microvolts using the spectral or modified moving average method.
Abbreviations: AF: Atrial fibrillation, ECG: Electrocardiography, HF: High-frequency, HRV=Heart rate variability, LF: Low-frequency, MI: Myocardial infarction, PRSA: Phase-rectified signal averaging, RMSSD: Root mean square of successive differences; SDNN: Standard deviation of all normal-to-normal (NN) intervals; VPB: Ventricular premature beat.

cardiovascular disease but also highlight potential targets for therapeutic intervention.

3. Clinical manifestations and associated cardiovascular diseases

Autonomic dysfunction manifests across a wide spectrum of cardiovascular diseases, often serving both as a contributor to pathogenesis and as a prognostic marker. These clinical expressions highlight the pervasive influence of autonomic regulation on cardiovascular health. Subtle alterations in autonomic tone can translate into clinically significant outcomes, making its assessment relevant not only for understanding mechanisms but also for guiding therapy (Figure 3).

3.1. Hypertension and orthostatic hypotension

Sympathetic overactivity is a well-established hallmark of essential hypertension, driving increased vascular resistance and promoting end-organ damage.[15,16] In many patients, heightened sympathetic tone precedes the clinical diagnosis of hypertension, suggesting a causal role. By contrast, failure of sympathetic reflex activation underlies orthostatic hypotension, a condition characterized by an excessive drop in blood pressure upon standing. This impairment reflects defective baroreflex buffering, diminished norepinephrine release, or both. Orthostatic hypotension not only impairs quality of life through recurrent dizziness and falls but is also strongly linked to adverse cardiovascular outcomes, including stroke and mortality.[17,18] Thus, hypertension and orthostatic hypotension may be viewed as two ends of a spectrum of autonomic imbalance, where one reflects excessive activation and the other inadequate compensatory response.

3.2. Ischemic heart disease and acute myocardial infarction

Autonomic dysfunction is closely intertwined with both the development and prognosis of ischemic heart disease and acute MI. Large population-based cohorts, most notably the Framingham Heart Study, have shown that reduced HRV significantly increases the risk of incident coronary artery disease and fatal cardiac outcomes.[11] Depressed vagal tone, impaired baroreflex sensitivity, and heightened sympathetic activation promote endothelial



Figure 3. The major clinical consequences of autonomic imbalance. The figure illustrates how sympathetic–parasympathetic dysregulation contributes to hypertension or orthostatic hypotension, heart failure, arrhythmias (AF, VT, SCD), and systemic disorders such as diabetes and neurodegeneration—ultimately leading to increased cardiovascular morbidity and mortality.
Abbreviations: AF: Atrial fibrillation; SCD: Sudden cardiac death; VT: Ventricular tachycardia.

dysfunction, enhance inflammatory activity, and increase myocardial oxygen demand, thereby facilitating ischemic progression and plaque instability.[11,12]

In the post-infarction setting, autonomic markers provide strong prognostic value. The Autonomic Tone and Reflexes after Myocardial Infarction Trial demonstrated that both reduced baroreflex sensitivity and markedly depressed HRV independently predict cardiac mortality after acute MI, regardless of left ventricular ejection fraction.[4] Similarly, analyses from the UK-Heart study confirmed that diminished autonomic modulation strongly correlates with total mortality and sudden cardiac death in post-MI patients, offering prognostic information complementary to traditional clinical measures.[19]

More recent work has highlighted the utility of deceleration capacity and heart rate turbulence—two refined indices of autonomic function—as superior predictors of post-MI mortality compared with standard HRV parameters.[20,21] These findings collectively indicate that autonomic imbalance is not merely a consequence of myocardial ischemia but also contributes to arrhythmogenesis, adverse remodeling, and long-term cardiovascular risk. Integrating autonomic indices into the evaluation of patients with ischemic heart disease or acute MI enhances risk stratification and may support more individualized monitoring and therapeutic decision-making.

3.3. Heart Failure

In chronic heart failure, autonomic dysfunction is both a marker of disease severity and a driver of progression. Reduced vagal tone and sustained sympathetic activation accelerate maladaptive remodeling, worsen arrhythmic risk, and predict mortality.[5,22] Importantly, autonomic indices such as baroreflex sensitivity and HRV provide prognostic information beyond conventional measures of left ventricular function.[4,23] The interplay between impaired autonomic regulation and neurohormonal activation also contributes to sodium retention, increased afterload, and progressive myocardial injury. Therapies that modulate autonomic tone—such as beta-blockers or vagal stimulation—demonstrate significant benefit in this population, underscoring the central role of the ANS in heart failure pathophysiology. Recognition of autonomic dysfunction in heart failure thus provides both a therapeutic target and a prognostic signal.

3.4. Arrhythmias

Autonomic imbalance exerts a profound influence on cardiac electrophysiology. Sympathetic activation shortens refractory periods and increases triggered activity, while vagal withdrawal diminishes protective mechanisms against arrhythmia.[14] The heterogeneity of autonomic input to the atria and ventricles creates a substrate for both atrial and ventricular arrhythmias. Atrial fibrillation is particularly linked with heightened sympathetic tone and reduced HRV, with autonomic modulation emerging as a therapeutic target.[24,25] Ventricular arrhythmias and sudden cardiac death have also been associated with impaired autonomic control, especially in post-MI patients.[10,26] In this context, autonomic markers not only reflect arrhythmic risk but also identify patients who may benefit from closer monitoring or device therapy.

3.5. Diabetic and neurodegenerative autonomic neuropathies

Diabetes mellitus frequently leads to cardiovascular autonomic neuropathy, a condition marked by impaired HRV, reduced baroreflex sensitivity, and increased risk of silent myocardial ischemia.[6,27] This silent ischemia underscores the clinical challenge, as patients may present with advanced disease without typical anginal symptoms. Similarly, neurodegenerative diseases such as Parkinson's and multiple system atrophy often involve autonomic pathways, contributing to orthostatic hypotension, arrhythmias, and sudden death.[28] These systemic disorders illustrate how autonomic dysfunction can serve as a shared mechanism linking diverse disease states with cardiovascular morbidity. The convergence of metabolic and neurodegenerative pathways on autonomic circuits highlights the vulnerability of cardiovascular regulation and emphasizes the need for routine evaluation of autonomic function in these populations (Table 3).

Age, sex, and race-related differences influence both autonomic dysfunction and its cardiovascular manifestations. Aging is associated with reduced baroreflex sensitivity, increased arterial stiffness, and a shift toward sympathetic predominance. Women generally demonstrate higher resting vagal tone compared with men, but experience a pronounced autonomic decline after menopause, while men exhibit earlier sympathetic predominance during midlife. Race-related variations have also been documented; individuals of African ancestry display lower baroreflex sensitivity and higher sympathetic activity, contributing to a higher burden of hypertension and arrhythmia susceptibility.[29,30] These demographic factors help contextualize the heterogeneous presentation and clinical trajectory of autonomic dysfunction across populations.

4. Diagnostic and monitoring tools

Accurate assessment of autonomic function is essential both for understanding disease mechanisms and for guiding therapeutic strategies. Over the past decades, diagnostic approaches have evolved from classical bedside maneuvers to advanced digital monitoring systems.

Table 3. Systemic diseases affecting autonomic function

Systemic disorder	Mechanism of autonomic involvement	Cardiovascular impact
Diabetes mellitus	Neuropathy of vagal fibers	Silent ischemia, arrhythmias
Parkinson's disease	Central autonomic degeneration	Orthostatic hypotension
Rheumatoid arthritis	Chronic inflammation→cytokine excess	HRV reduction, vascular dysfunction
Chronic kidney disease	Sympathetic overactivation	Hypertension, LV hypertrophy

Abbreviations: HRV: Heart rate variability; LV: Left ventricle.

Current international guidelines and scientific statements acknowledge the prognostic value of autonomic function testing in selected cardiovascular populations. Heart rate variability (HRV) and baroreflex sensitivity are recognized as validated autonomic markers for risk stratification after MI and in chronic heart failure, providing prognostic information independent of left ventricular ejection fraction and conventional clinical variables.[31] In post-MI settings, advanced autonomic indices such as heart rate turbulence and deceleration capacity are recommended for refined autonomic and arrhythmic risk assessment, particularly for sudden cardiac death prediction.[32,33] While routine autonomic testing is not universally recommended for all patients, the current guideline-oriented approaches support its use in high-risk populations and research-driven personalized risk stratification strategies, especially when autonomic markers are integrated with clinical, imaging, and functional parameters.[31]

4.1. Heart rate variability and baroreflex sensitivity

Heart rate variability (HRV) remains the most widely used noninvasive marker of autonomic function. Time- and frequency-domain analyses of HRV provide insights into sympathetic–parasympathetic balance and have been consistently linked with cardiovascular morbidity and mortality.[10,34] Reduced HRV is particularly valuable in identifying post-MI patients at risk for sudden cardiac death.[26] Baroreflex sensitivity testing, usually performed with vasoactive drugs or spontaneous sequence methods, quantifies reflexive heart rate changes in response to blood pressure fluctuations. Impaired baroreflex sensitivity has strong prognostic significance in conditions such as chronic heart failure and hypertension.[4,23,31]

4.2. Heart rate acceleration, deceleration capacity, and heart rate turbulence

Beyond traditional indices such as HRV and baroreflex sensitivity, several advanced autonomic markers provide additional prognostic insights into cardiovascular risk. Heart rate acceleration (HRA) and heart rate deceleration capacity quantify short-term beat-to-beat fluctuations reflecting sympathetic activation and vagal modulation, respectively. Deceleration capacity, derived through phase-rectified signal averaging, has been shown to be a strong predictor of post-MI mortality, outperforming conventional HRV indices in large cohort studies.[20,35] Reduced deceleration capacity reflects impaired vagal braking and heightened vulnerability to arrhythmic events.

Heart rate turbulence—comprising turbulence onset and turbulence slope—assesses baroreflex-mediated sinus rhythm changes following ventricular premature beats. Abnormal heart rate turbulence indicates impaired autonomic–baroreflex coupling and has demonstrated robust prognostic value after acute MI. Seminal work by Barthel *et al.* demonstrated that abnormal turbulence parameters independently predict mortality in post-MI patients, even after adjustment for left ventricular ejection fraction (LVEF) and standard autonomic markers.[32,33] Together, these measures complement traditional HRV analysis and provide a deeper characterization of autonomic imbalance relevant to ischemic heart disease, arrhythmogenesis, and sudden cardiac death. The physiological basis, measurement techniques, and prognostic relevance of HRV, acceleration capacity, deceleration capacity, and heart rate turbulence are derived from landmark cohort studies and methodological analyses.[20,32-34]

4.3. Tilt-table testing and microneurography

Tilt-table testing allows evaluation of orthostatic intolerance syndromes, including vasovagal syncope and orthostatic hypotension. By provoking controlled positional changes, this method reveals autonomic contributions to cardiovascular instability.[17,36] Microneurography, though technically demanding, enables direct recording of sympathetic nerve traffic. It has provided fundamental insights into sympathetic overactivity in hypertension and heart failure.[37]

4.4. Ambulatory and wearable monitoring

Twenty-four-hour Holter monitoring has traditionally been employed to assess HRV, arrhythmia burden, and autonomic patterns across circadian cycles. More recently, wearable sensors have expanded the possibilities of continuous autonomic assessment in both clinical and community settings.[7,38] These devices, often integrated with AI algorithms, can detect subtle shifts in autonomic regulation, providing opportunities for early intervention and remote monitoring.[39]

4.5. Emerging digital biomarkers

Novel techniques are now being developed to quantify autonomic function with greater precision. Machine learning algorithms applied to electrocardiography and photoplethysmography signals can capture nonlinear dynamics of autonomic regulation beyond conventional indices.[40] In addition, multimodal platforms integrating hemodynamic, neural, and biochemical data are emerging as potential tools for personalized risk stratification.[41]

5. Therapeutic and prognostic implications

Autonomic dysfunction is both a mechanistic driver of cardiovascular disease and an attractive therapeutic target. Clinical efforts have increasingly focused on strategies to restore autonomic balance, with the dual aim of improving symptoms and enhancing long-term outcomes. Correction of autonomic imbalance is not only a supportive therapy but also an intervention at the level of disease mechanisms, potentially altering prognosis in a broad spectrum of cardiovascular conditions (Figure 4).

5.1. Pharmacologic modulations

Beta-adrenergic receptor antagonists remain a cornerstone in the treatment of conditions characterized by sympathetic overdrive, such as heart failure and post-MI states. Beyond their hemodynamic benefits, beta-blockers reduce arrhythmic risk by restoring vagal predominance and mitigating sympathetic activation.[5,22,42] Their impact extends to improved survival, fewer hospitalizations, and enhanced functional capacity. Importantly, beta-blockers exemplify how targeting autonomic pathways translates into tangible clinical benefit.

Other pharmacologic interventions, including renin-angiotensin-aldosterone system (RAAS) inhibitors, exert indirect autonomic effects by reducing neurohormonal activation and vascular stiffness.[43] By unloading the heart and improving vascular compliance, these drugs reduce sympathetic drive and favorably influence baroreflex sensitivity. In combination with beta-blockers, RAAS inhibitors form the backbone of guideline-directed therapy for heart failure and post-infarction patients, in part due to their complementary actions on autonomic regulation.

Emerging evidence also points to the potential of anti-inflammatory therapies in improving autonomic markers such as HRV and baroreflex sensitivity.[12,44] Since chronic inflammation promotes sympathetic activation and blunts vagal tone, modulation of inflammatory pathways may represent an indirect but powerful mechanism for restoring autonomic balance. Anti-inflammatory strategies, therefore, may not only stabilize cardiovascular disease progression but also enhance resilience against arrhythmias and sudden cardiac death.

Taken together, pharmacologic modulation of autonomic tone highlights the therapeutic value of integrating hemodynamic, neurohormonal, and inflammatory pathways. The convergence of these mechanisms reinforces the concept that therapies effective in cardiovascular disease often achieve their benefit, at least in part, through autonomic rebalancing. Recognizing

and leveraging this connection may help refine current strategies and guide the development of novel treatments that place autonomic function at the center of cardiovascular therapeutics.

5.2. Non-pharmacologic interventions

Exercise training is one of the most effective non-pharmacologic approaches to enhance vagal tone and improve HRV. Cardiac rehabilitation programs have consistently demonstrated improvements in autonomic balance, contributing to reduced morbidity and mortality in patients with cardiovascular disease.[45] Neuromodulatory therapies, such as baroreflex activation therapy and vagal nerve stimulation, are being actively investigated. These interventions aim to directly modulate neural pathways to rebalance autonomic control, with promising results in heart failure and resistant hypertension.[46,47] In addition, catheter-based renal denervation has shown potential for reducing sympathetic drive in patients with resistant hypertension, though long-term efficacy remains under evaluation[48] (Table 4).

5.3. Neuromodulation-based non-pharmacologic interventions

In addition to exercise and device-based therapies, several non-pharmacologic neuromodulation strategies have been developed to influence autonomic balance. Acoustic stimulation, particularly low-frequency vibroacoustic input, has been shown to enhance vagal activity and reduce sympathetic arousal through brainstem auditory-autonomic pathways.[49,50] Photic neuromodulation, including near-infrared and flicker-light stimulation, can modulate cortical-autonomic circuits and improve HRV in experimental and early clinical contexts.[51]

Electrical stimulation modalities, such as transcutaneous vagus nerve stimulation (tVNS) and transcutaneous electrical nerve stimulation (TENS), provide non-invasive methods to activate parasympathetic fibers and improve autonomic markers including HRV and baroreflex sensitivity.[52] Magnetic neuromodulation, particularly repetitive transcranial magnetic stimulation (rTMS), has been shown to modify central autonomic networks,

Figure 4. Overview of major therapeutic approaches to autonomic imbalance, classified into pharmacologic (beta-blockers, RAAS inhibitors, anti-inflammatory agents), non-pharmacologic (exercise, rehabilitation), and device-based interventions (baroreflex activation, vagal stimulation, renal denervation)
Abbreviation: RAAS: Renin-angiotensin-aldosterone system.

Table 4. Therapeutic interventions and autonomic effects

Intervention	Mechanism of ANS	Evidence of benefit	Limitations/drawbacks
Beta-blockers	Reduce sympathetic drive, enhance vagal tone	Strong evidence in HF, post-MI	Bradycardia, fatigue, exercise intolerance; limited effect in some preserved EF populations
Exercise training	Improves vagal tone, HRV	Effective in rehab programs	Requires adherence; variability in response; limited effect in severe frailty
Vagal stimulation	Direct parasympathetic activation	Promising in HF trials	Device invasiveness or tolerability issues; long-term outcomes remain uncertain
Renal denervation	Sympathetic suppression	Mixed trial results, ongoing	Procedural variability; inconsistent trial findings; not universally effective
Meditation/Biofeedback	Stress reduction, vagal enhancement	Emerging supportive evidence	Heterogeneity in protocols; patient engagement required; modest effect sizes

Abbreviations: ANS: Autonomic nervous system; EF: Ejection fraction; HF: Heart failure; MI: Myocardial infarction; HRV: Heart rate variability.

decreasing sympathetic tone and improving cardiovascular autonomic regulation in small human trials.[53]

Finally, thermal modulation and biofeedback-based autonomic retraining techniques—including paced breathing, skin-temperature biofeedback, and HRV biofeedback—have demonstrated consistent benefits in reducing sympathetic activity and enhancing vagal function.[54] Collectively, these approaches highlight an emerging spectrum of non-invasive neuromodulation strategies with relevance for autonomic dysfunction and cardiometabolic risk.

5.4. Bioelectronic and wearable neuromodulation technologies

Recent advances in bioelectronic medicine have introduced smart wearable materials capable of interfacing directly with the cardiovascular and autonomic systems. Among these, electroconductive polymers such as PEDOT: PSS have emerged as promising platforms due to their high biocompatibility, mechanical flexibility, and ability to form stable, low-impedance skin or tissue interfaces. These materials enable continuous, high-fidelity monitoring of autonomic signals, including heart-rate dynamics and electrophysiological fluctuations, thereby expanding the diagnostic utility of non-invasive neuromodulation approaches. Beyond monitoring, next-generation wearable bioelectronic systems are being developed to deliver localized electrical or electrophysiological modulation aimed at stabilizing cardiac conduction. Recent experimental evidence suggests that such platforms may support the prevention, suppression, or even healing of post-infarct ventricular arrhythmias by providing adaptive electrotherapy or microstimulation directly over the infarct border zone. These emerging technologies illustrate a translational pathway in which autonomic assessment and therapeutic neuromodulation converge, complementing existing device-based and pharmacologic interventions and representing a future direction for personalized cardiovascular care.[55,56]

5.5. Prognostic role of autonomic markers

Autonomic markers provide powerful prognostic information across a variety of cardiovascular conditions. Reduced HRV and impaired baroreflex sensitivity independently predict mortality after MI, beyond traditional risk factors.[4,19,26] Similarly, autonomic indices enhance risk stratification in heart failure, sudden cardiac death, and atrial fibrillation populations.[10,14,24,57] With the integration of wearable technologies and AI-based analytics, autonomic markers are increasingly being considered for incorporation into personalized prognostic models, potentially guiding therapy in real time.[7,38,58]

6. Future directions

The integration of autonomic markers into precision cardiology represents a promising frontier. Emerging technologies allow for real-time acquisition of autonomic signals using wearable devices, while machine learning approaches enhance the extraction of clinically meaningful patterns.[7,38,58,59] These advances could pave the way for dynamic risk prediction models that continuously adapt to an individual's physiological state.

Another critical avenue is the combination of autonomic assessment with multimodal data—such as genomic, proteomic, and imaging biomarkers—to create comprehensive phenotypic profiles.[57,60] Such integration could improve the understanding of patient heterogeneity and help identify subgroups most likely to benefit from specific therapies.

Interventional strategies are also expanding. Neuromodulation, renal denervation, and vagal stimulation are under active investigation, with ongoing trials aiming to define optimal patient populations, dosing parameters, and long-term safety.[46-48,61] In parallel, anti-inflammatory and antioxidant therapies may offer novel means of restoring autonomic balance by addressing upstream molecular pathways.[12,13,44,62]

7. Conclusion

Autonomic dysfunction is a central mechanism linking diverse cardiovascular diseases, including hypertension, heart failure, arrhythmias, and systemic conditions such as diabetes and neurodegenerative disorders. Its clinical importance lies not only in its contribution to disease pathogenesis but also in its value as a prognostic marker and therapeutic target.

The future of cardiovascular medicine will likely involve deeper integration of autonomic assessment into routine care, supported by digital health platforms and personalized analytics. By combining mechanistic insights with innovative technologies, clinicians may be able to anticipate decompensation, guide therapy in real time, and ultimately improve outcomes.

In conclusion, autonomic dysfunction should be recognized as both a unifying mechanism and an opportunity for therapeutic innovation. Continued interdisciplinary research, spanning molecular biology to digital health, will be essential in realizing its potential as a cornerstone of personalized cardiovascular medicine.

Acknowledgments

None.

Funding

None.

Conflict of interest

The authors declare that they have no competing interests.

Author contributions

Conceptualization: Abdülmelik Birgün, Mucahit Yetim, Lütfü Bekar
Visualization: Abdülmelik Birgün, Macit Kalçık
Writing–original draft: Abdülmelik Birgün, Muhammet Cihat Çelik, Macit Kalçık
Writing–review & editing: Macit Kalçık, Lütfü Bekar, Yusuf Karavelioğlu

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Availability of data

Not applicable.

References

1. Goldberger JJ, Arora R, Buckley U, Shivkumar K. Autonomic nervous system dysfunction: JACC focus seminar. *J Am Coll Cardiol*. 2019;73(10):1189-1206.

   doi: 10.1016/j.jacc.2018.12.064

2. Roth GA, Mensah GA, Johnson CO, *et al*. Global burden of cardiovascular diseases and risk factors, 1990-2019: Update from the GBD 2019 study. *J Am Coll Cardiol*. 2020;76(25):2982-3021.

   doi: 10.1016/j.jacc.2020.11.010

3. Freeman R. Clinical practice. Neurogenic orthostatic hypotension. *N Engl J Med*. 2008;358(6):615-624.

   doi: 10.1056/nejmcp074189

4. La Rovere MT, Bigger JT Jr., Marcus FI, Mortara A, Schwartz PJ. Baroreflex sensitivity and heart-rate variability in prediction of total cardiac mortality after myocardial infarction. ATRAMI (autonomic tone and reflexes after myocardial ınfarction) investigators. *Lancet*. 1998;351(9101):478-484.

   doi: 10.1016/s0140-6736(97)11144-8

5. Florea VG, Cohn JN. The autonomic nervous system and heart failure. *Circ Res*. 2014;114(11):1815-1826.

   doi: 10.1161/cırcresaha.114.302589

6. Vinik AI, Ziegler D. Diabetic cardiovascular autonomic neuropathy. *Circulation*. 2007;115(3):387-397.

   doi: 10.1161/cırculatıonaha.106.634949

7. Hughes A, Shandhi MM, Master H, Dunn J, Brittain E. Wearable devices in cardiovascular medicine. *Circ Res*. 2023;132(5):652-670.

   doi: 10.1161/cırcresaha.122.322389

8. La Rovere MT, Pinna GD, Maestri R, *et al*. Prognostic implications of baroreflex sensitivity in heart failure patients in the beta-blocking era. *J Am Coll Cardiol*. 2009;53(2):193-199.

   doi: 10.1016/j.jacc.2008.09.034

9. Mitchell GF. Arterial stiffness and wave reflection: Biomarkers of cardiovascular risk. *Artery Res*. 2009;3(2):56-64.

   doi: 10.1016/j.artres.2009.02.002

10. Thayer JF, Yamamoto SS, Brosschot JF. The relationship of autonomic imbalance, heart rate variability and cardiovascular disease risk factors. *Int J Cardiol*. 2010;141(2):122-131.

    doi: 10.1016/j.ijcard.2009.09.543

11. Tsuji H, Larson MG, Venditti FJ Jr., *et al*. Impact of reduced heart rate variability on risk for cardiac events. The Framingham heart study. *Circulation*. 1996;94(11):2850-2855.

    doi: 10.1161/01.cir.94.11.2850

12. Tracey KJ. The inflammatory reflex. *Nature*. 2002;420(6917):853-859.

    doi: 10.1038/nature01321

13. Montezano AC, Touyz RM. Reactive oxygen species, vascular Noxs, and hypertension: Focus on translational and clinical research antioxid redox signal. *Antioxid Redox Signal*. 2014;20(1):164-182.

    doi: 10.1089/ars.2013.5302

14. Shen MJ, Zipes DP. Role of the autonomic nervous system in modulating cardiac arrhythmias. *Circ Res*. 2014;114(6):1004-1021.

    doi: 10.1161/cırcresaha.113.302549

15. Grassi G, Mark A, Esler M. The sympathetic nervous system alterations in human hypertension. *Circ Res*. 2015;116(6):976-990.

    doi: 10.1161/cırcresaha.116.303604

16. Esler M. The sympathetic system and hypertension. *Am J Hypertens*. 2000;13(6 Pt 2):99S-105S.

    doi: 10.1016/s0895-7061(00)00225-9

17. Fedorowski A. Postural orthostatic tachycardia syndrome: Clinical presentation, aetiology and management. *J Intern Med*. 2019;285(4):352-366.

doi: 10.1111/joim.12852

18. Rose KM, Tyroler HA, Nardo CJ, *et al*. Orthostatic hypotension and the incidence of coronary heart disease: The atherosclerosis risk in communities study. *Am J Hypertens*. 2000;13(6 Pt 1):571-578.

doi: 10.1016/s0895-7061(99)00257-5

19. Nolan J, Batin PD, Andrews R, *et al*. Prospective study of heart rate variability and mortality in chronic heart failure: Results of the United Kingdom heart failure evaluation and assessment of risk trial (UK-heart). *Circulation*. 1998;98(15):1510-1516.

doi: 10.1161/01.cir.98.15.1510

20. Bauer A, Kantelhardt JW, Barthel P, *et al*. Deceleration capacity of heart rate as a predictor of mortality after myocardial infarction: Cohort study. *Lancet*. 2006;367(9523):1674-1681.

doi: 10.1016/S0140-6736(06)68735-7

21. Goldhaber SZ, Visani L, De Rosa M. Acute pulmonary embolism: clinical outcomes in the ınternational cooperative pulmonary embolism registry (ICOPER). *Lancet*. 1999;353(9162):1386-1389.

doi: 10.1016/s0140-6736(98)07534-5

22. Triposkiadis F, Karayannis G, Giamouzis G, Skoularigis J, Louridas G, Butler J. The sympathetic nervous system in heart failure physiology, pathophysiology, and clinical implications. *J Am Coll Cardiol*. 2009;54(19):1747-1762.

doi: 10.1016/j.jacc.2009.05.015

23. Mortara A, La Rovere MT, Pinna GD, *et al*. Arterial baroreflex modulation of heart rate in chronic heart failure: Clinical and hemodynamic correlates and prognostic implications. *Circulation*. 1997;96(10):3450-3458.

doi: 10.1161/01.cir.96.10.3450

24. Chen PS, Chen LS, Fishbein MC, Lin SF, Nattel S. Role of the autonomic nervous system in atrial fibrillation: pathophysiology and therapy. *Circ Res*. 2014;114(9):1500-1515.

doi: 10.1161/cırcresaha.114.303772

25. Coumel P. Autonomic influences in atrial tachyarrhythmias. *J Cardiovasc Electrophysiol*. 1996;7(10):999-1007.

doi: 10.1111/j.1540-8167.1996.tb00474.x

26. Schwartz PJ, La Rovere MT, Vanoli E. Autonomic nervous system and sudden cardiac death. Experimental basis and clinical observations for post-myocardial infarction risk stratification. *Circulation*. 1992;85(1 Suppl):I77-I91.

27. Spallone V, Ziegler D, Freeman R, *et al*. Cardiovascular autonomic neuropathy in diabetes: Clinical impact, assessment, diagnosis, and management. *Diabetes Metab Res Rev*. 2011;27(7):639-653.

doi: 10.1002/dmrr.1239

28. Kaufmann H, Biaggioni I. Autonomic failure in neurodegenerative disorders. *Semin Neurol*. 2003;23(4):351-363.

doi: 10.1055/s-2004-817719

29. Taylor CE, Arnold AC, Fu Q, Shibao CA. Sex differences in cardiovascular autonomic control: İntroduction to the special issue. *Clin Auton Res*. 2020;30(5):365-367.

doi: 10.1007/s10286-020-00732-y

30. Farrell MC, Giza RJ, Shibao CA. Race and sex differences in cardiovascular autonomic regulation. *Clin Auton Res*. 2020;30(5):371-379.

doi: 10.1007/s10286-020-00723-z

31. La Rovere MT, Pinna GD, Raczak G. Baroreflex sensitivity: Measurement and clinical implications. *Ann Noninvasive Electrocardiol*. 2008;13(2):191-207.

doi: 10.1111/j.1542-474X.2008.00219.x

32. Barthel P, Schneider R, Bauer A, *et al*. Risk stratification after acute myocardial infarction by heart rate turbulence. *Circulation*. 2003;108(10):1221-1226.

doi: 10.1161/01.CIR.0000088783.34082.89

33. Wichterle D, Melenovsky V, Malik M. Mechanisms involved in heart rate turbulence. *Card Electrophysiol Rev*. 2002;6(3):262-266.

doi: 10.1023/a:1016385126668

34. Malik M, Camm AJ. Heart rate variability and clinical cardiology. *Br Heart J*. 1994;71(1):3-6.

doi: 10.1136/hrt.71.1.3

35. Perkiömäki JS, Zareba W, Ruta J, *et al*. Fractal and complexity measures of heart rate dynamics after acute myocardial infarction. *Am J Cardiol*. 2001;88(7):777-781.

doi: 10.1016/s0002-9149(01)01851-3

36. Benditt DG, Nguyen JT. Syncope: Therapeutic approaches. *J Am Coll Cardiol*. 2009;53(19):1741-1751.

doi: 10.1016/j.jacc.2008.12.065

37. Vallbo AB, Hagbarth KE, Torebjörk HE, Wallin BG. Somatosensory, proprioceptive, and sympathetic activity in human peripheral nerves. *Physiol Rev*. 1979;59(4):919-957.

doi: 10.1152/physrev.1979.59.4.919

38. Steinhubl SR, Waalen J, Edwards AM, *et al*. Effect of a home-based wearable continuous ECG monitoring patch on detection of undiagnosed atrial fibrillation: The mSToPS randomized clinical trial. *JAMA*. 2018;320(2):146-155.

doi: 10.1001/jama.2018.8102

39. Piwek L, Ellis DA, Andrews S, Joinson A. The rise of consumer health wearables: Promises and barriers. *PLoS*

Med. 2016;13(2):e1001953.

doi: 10.1371/journal.pmed.1001953

40. Rajendra Acharya U, Paul Joseph K, Kannathal N, Lim CM, Suri JS. Heart rate variability: A review. *Med Biol Eng Comput*. 2006;44(12):1031-1051.

doi: 10.1007/s11517-006-0119-0

41. Huikuri HV, Stein PK. Clinical application of heart rate variability after acute myocardial infarction. *Front Physiol*. 2012;3:41.

doi: 10.3389/fphys.2012.00041

42. Packer M, Coats AJ, Fowler MB, *et al*. Effect of carvedilol on survival in severe chronic heart failure. *N Engl J Med*. 2001;344(22):1651-1658.

doi: 10.1056/nejm200105313442201

43. Grassi G, Quarti-Trevano F, Seravalle G, *et al*. Early sympathetic activation in the initial clinical stages of chronic renal failure. *Hypertension*. 2011;57(4):846-851.

doi: 10.1161/hypertensıonaha.110.164780

44. Ridker PM, Everett BM, Thuren T, *et al*. Antiinflammatory therapy with canakinumab for atherosclerotic disease. *N Engl J Med*. 2017;377(12):1119-1131.

doi: 10.1056/nejmoa1707914

45. Iellamo F, Manzi V, Caminiti G, *et al*. Dose-response relationship of baroreflex sensitivity and heart rate variability to individually-tailored exercise training in patients with heart failure. *Int J Cardiol*. 2013;166(2):334-339.

doi: 10.1016/j.ijcard.2011.10.082

46. Heusser K, Tank J, Engeli S, *et al*. Carotid baroreceptor stimulation, sympathetic activity, baroreflex function, and blood pressure in hypertensive patients. *Hypertension*. 2010;55(3):619-626.

doi: 10.1161/hypertensıonaha.109.140665

47. De Ferrari GM, Crijns HJ, Borggrefe M, *et al*. Chronic vagus nerve stimulation: A new and promising therapeutic approach for chronic heart failure. *Eur Heart J*. 2011;32(7):847-855.

doi: 10.1093/eurheartj/ehq391

48. Böhm M, Ewen S, Kindermann I, Linz D, Ukena C, Mahfoud F. Renal denervation and heart failure. *Eur J Heart Fail*. 2014;16(6):608-613.

doi: 10.1002/ejhf.83

49. Vilímek Z, Kantor J, Krejčí J, *et al*. The effect of low frequency sound on heart rate variability and subjective perception: A randomized crossover study. *Healthcare (Basel)*. 2022;10(6):1024.

doi: 10.3390/healthcare10061024

50. Niu M, Zhao R, Wang J. The effects of a music intervention on the autonomic nervous system during recovery from strenuous exercise. *Ann Noninvasive Electrocardiol*. 2024;29(1):e13096.

doi: 10.1111/anec.13096

51. Martins V, Allen MS, Borges U, *et al*. Effects of light exposure on vagally-mediated heart rate variability: A systematic review. *Neurosci Biobehav Rev*. 2025;176:106241.

doi: 10.1016/j.neubiorev.2025.106241

52. Clancy JA, Mary DA, Witte KK, Greenwood JP, Deuchars SA, Deuchars J. Non-invasive vagus nerve stimulation in healthy humans reduces sympathetic nerve activity. *Brain Stimul*. 2014;7(6):871-877.

doi: 10.1016/j.brs.2014.07.031

53. Lee H, Lee JH, Hwang MH, Kang N. Repetitive transcranial magnetic stimulation improves cardiovascular autonomic nervous system control: A meta-analysis. *J Affect Disord*. 2023;339:443-453.

doi: 10.1016/j.jad.2023.07.039

54. Chen S, Sun P, Wang S, Lin G, Wang T. Effects of heart rate variability biofeedback on cardiovascular responses and autonomic sympathovagal modulation following stressor tasks in prehypertensives. *J Hum Hypertens*. 2016;30(2):105-111.

doi: 10.1038/jhh.2015.27

55. Lopez-Buenafe GR, Alonso-Cabrera JA, Marcuello C, *et al*. Fabrication and characterization of PEDOT: PSS-based microstructured electrodes for *in vitro* cell culture. *Adv Mater Interfaces*. 2025;12(20):e202500097.

doi: 10.1002/admi.202500097

56. Roshanbinfar K, Schiffer M, Carls E, *et al*. Electrically conductive collagen-PEDOT: PSS hydrogel prevents post-ınfarct cardiac arrhythmia and supports hiPSC-cardiomyocyte function. *Adv Mater*. 2024;36(28):e2403642.

doi: 10.1002/adma.202403642

57. Huikuri HV, Castellanos A, Myerburg RJ. Sudden death due to cardiac arrhythmias. *N Engl J Med*. 2001;345(20):1473-1482.

doi: 10.1056/nejmra000650

58. Stein PK, Domitrovich PP, Huikuri HV, Kleiger RE, Cast Investigators. Traditional and nonlinear heart rate variability are each independently associated with mortality after myocardial infarction. *J Cardiovasc Electrophysiol*. 2005;16(1):13-20.

doi: 10.1046/j.1540-8167.2005.04358.x

59. Ishaque S, Khan N, Krishnan S. Trends in heart-rate variability signal analysis. *Front Digit Health*. 2021;3:639444.

doi: 10.3389/fdgth.2021.639444

60. Assimes TL, Roberts R. Genetics: Implications for prevention and management of coronary artery disease. *J Am Coll Cardiol*. 2016;68(25):2797-2818.

doi: 10.1016/j.jacc.2016.10.039

61. Abraham WT, Zile MR, Weaver FA, *et al*. Baroreflex activation therapy for the treatment of heart failure with a reduced ejection fraction. *JACC Heart Fail*. 2015;3(6):487-496.
doi: 10.1016/j.jchf.2015.02.006

62. Madamanchi NR, Runge MS. Mitochondrial dysfunction in atherosclerosis. *Circ Res*. 2007;100(4):460-473.
doi: 10.1161/01.RES.0000258450.44413.96